MedTrace Logo

Pharmacological Intervention in Diabetic Retinopathy

NCT00619034 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2010-12-29

No results posted yet for this study

Summary

The purpose of this study is to determine if diabetic retinopathy can be treated with prostaglandin analogues, prostaglandin synthesis inhibitors or carbonic anhydrases inhibitors.

Conditions

Interventions

DRUG

Latanoprost, diclofenac and dorzolamide (eyedrops)

1 eyedrop twice daily in one week

DRUG

Diclofenac

dicolfenac eyedrops twice daily i one eye

DRUG

Dorzolamide

dorzolamide eyedrops twice daily, in one eye for one week

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Kathrine K Tilma, MD · Department of Ophthalmology - Aarhus, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619034 on ClinicalTrials.gov